Is Ozempic (semaglutide) safe?

Ozempic® can be considered safe given it has been rigorously tested in clinical trials to evaluate both its safety and efficacy before receiving FDA-approval and entering the market for widespread use. All medications carry potential risks and side effects, so it is no surprise that this is also the case with Ozempic. Common side effects of Ozempic include nausea, vomiting, constipation, diarrhea, and heartburn. More serious side effects are rare but include gallbladder disease such as cholecystitis (infection of the gallbladder). In a clinical trial, cholecystitis occurred in approximately 1.5% of patients taking 0.5 mg of Ozempic and 0.4% of patients taking 1 mg of Ozempic. It is important to carefully review the potential risks as well as benefits of any medication with your medical provider before starting and assess for any possible drug-drug interactions with medications you may already be taking.

Form Health logo
ABOUT THE AUTHOR

Form Health

Form Health is a virtual obesity medicine clinic founded in 2019 that provides science-based obesity care to help patients achieve their weight loss and health goals. Patients have the opportunity to achieve sustainable weight loss by working closely with an American Board of Obesity Medicine physician and a Registered Dietitian who is a Board Certified Specialist in Obesity and Weight Management. Each Care Team develops a personalized treatment plan based on a comprehensive review of their medical history that includes behavioral support, nutrition, physical activity, and medication, if appropriate.

Doctor, healthy food,  man on a computer , and smiling women sitting on counter in baggy yellow sweatshirt

Find your Form

Take the first step to your healthier future.

Get Started
Disclaimer: The content made available on The Form Health Website represents the views and opinions of the authors and not those of other entities, such as the manufacturers of products mentioned therein.  
Ozempic® is a registered trademark of Novo Nordisk A/S.